Omnicell stock inched higher today, up about 2.6% to roughly $36.90 after posting its Q3 2026 report. On the surface it looked like a routine quarter. The real headline sat in profitability. Management delivered about $45 million of non GAAP EBITDA on roughly $308 million of sales, enough to lift full year earnings guidance.
Short term traders reacted to the beat and tweak to the outlook. Longer term investors will care more that Omnicell is squeezing more profit out of its medication management platform while still funding the multi year Titan XT and OmniSphere rollout.
Impressed that Omnicell pushed non GAAP EBITDA to roughly $45 million while still pouring cash into Titan XT and OmniSphere, yet want a wider set of profitable compounders to compare it against? You can check out our screener of resilient operators with solid cash generation in the list of solid balance sheet and fundamentals stocks (23 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$307.9 million vs. US$310.6 million (broadly flat year on year with a small decline).
-
Net Income, excl. extra items (Q3 2026 vs. Q3 2025):US$11.0 million vs. US$5.5 million (an increase of about 102% year on year).
-
Basic EPS (Q3 2026 vs. Q3 2025):US$0.24 vs. US$0.12 (an increase of about 101% year on year).
-
Trailing 12 month Net Income, excl. extra items (Q3 2026 vs. Q3 2025):US$44.7 million vs. US$23.1 million (an increase of about 93% over the last year).
Earnings only tell part of Omnicell's story, because the actual cash coming off the platform can paint a very different picture of what you are paying for NasdaqGS:OMCL today. When you focus purely on Omnicell's cash flows and the implied value of those streams, the stock could be a striking 39% undervalued .
Evaluating Omnicell's Titan XT Execution Milestones
The bullish view rests on Omnicell turning a product refresh into broader, software rich contracts that repair margins over time.
"The meaningfully larger product bookings pipeline that exited Q2 2026, built around Titan XT and OmniSphere centric proposals, gives Omnicell more opportunity to tilt future revenue toward multi product, software rich contracts that can support mix driven margin improvement."
Q3 results give partial proof. Product and service revenue were both solid, non GAAP EBITDA landed at US$45 million, and guidance for full year profitability moved higher without raising the already wide 2026 bookings target. Management still describes that target as back end weighted. That combination suggests early pipeline depth and cost discipline are supporting the margin repair leg of the thesis, even though large Titan XT deals are only just starting to ship.
The price and this Narrative do not agree. → Uncover what this Narrative says Omnicell is actually worth .
Omnicell Bear Case: Input Costs And Delays Under The Microscope
Bearish investors worry Omnicell will not get enough pricing or volume to offset longer sales cycles and rising components. The concern is clear.
"Bearish analysts expect Omnicell to struggle with rising input costs, elongated sales cycles, and intensified competition that together keep margins under pressure and limit any recovery in pricing power or market share."
Q3 margins did absorb roughly US$6 million of extra memory costs, yet non GAAP EBITDA still reached US$45 million and full year profitability guidance went up. That combination weakens the idea of immediate margin compression, although bookings remain back end weighted, so the fear on elongated deal timing is not resolved by this quarter.
Hunt For Quiet Compounding Setups
Omnicell recently highlighted how effective margin repair can reshape the impact of revenue changes. The real opportunity sits in evaluating stocks that could be undervalued before the market adjusts expectations.
-
Company 1 - 26% below our estimate - positions essential semiconductor components and software at key points where digital data is processed, interconnected, and protected at large scale.
-
Company 2 - 38% below our estimate - expands manufacturing capacity to support higher margin protective films and installation services for dealer and OEM distribution channels.
-
Company 3 - 31% below our estimate - converts long duration optical and solar supply agreements into higher margin glass and photonics shipments for digital and energy infrastructure projects.
Three companies from the same screener. Open every one of the 30 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include OMCL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
